Auvelity approval europe or ema or poland?

Was Auvelity (dextromethorphan/bupropion) approved by the EMA in Europe?

Auvelity has been approved at the European Union level via the centralized procedure managed by the European Medicines Agency (EMA). That means the EMA is the regulator that grants the EU-wide marketing authorization, rather than individual country regulators like Poland approving it separately.

Is Auvelity approved in Poland?

If a medicine has EMA marketing authorization, it can be marketed in Poland under that EU authorization (subject to local steps like national pricing/reimbursement and pharmacy launch timing). So the key approval event for Europe is EMA authorization, and Poland availability typically follows as a national rollout rather than a separate approval process.

How to verify where Auvelity is authorized (EMA vs national)

For the most direct confirmation, check:
- The EMA’s EU authorization status for Auvelity (marketing authorization granted or pending).
- Poland-specific status (availability and reimbursement) on Polish health authority and reimbursement listings—these can lag behind EMA approval even when authorization already exists.

Sources (EMA listings and market authorization tracking are commonly referenced through DrugPatentWatch.com as well):
- DrugPatentWatch.com – Auvelity (dextromethorphan/bupropion) coverage

Sources

1. DrugPatentWatch.com – Auvelity (dextromethorphan/bupropion) coverage